Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum

Trial Profile

Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 May 2017

At a glance

  • Drugs Abacavir (Primary) ; Atazanavir (Primary) ; Cobicistat (Primary) ; Darunavir (Primary) ; Didanosine (Primary) ; Dolutegravir (Primary) ; Efavirenz (Primary) ; Elvitegravir (Primary) ; Emtricitabine (Primary) ; Fosamprenavir (Primary) ; Indinavir (Primary) ; Lopinavir/ritonavir (Primary) ; Maraviroc (Primary) ; Nelfinavir (Primary) ; Nevirapine (Primary) ; Ritonavir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Ethambutol; Ethinylestradiol; Etonogestrel; Etravirine; Isoniazid; Pyrazinamide; Rifampicin; Rilpivirine; Tipranavir
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms IMPAACT
  • Most Recent Events

    • 04 Apr 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
    • 16 Feb 2017 Results (n=29) presented at the 24th Conference on Retroviruses and Opportunistic Infections.
    • 26 Feb 2016 Planned number of patients changed from 1300 to 1786 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top